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ABSTRACT
Background. PD-1 inhibitors are routinely used for the
treatment of advanced melanoma. This study sought to
determine whether PD-L1 expression on circulating tumor
cells (CTCs) can serve as a predictive biomarker of clinical
benefit and response to treatment with the PD-1 inhibitor
pembrolizumab.
Methods. Blood samples were collected from patients with
metastatic melanoma receiving pembrolizumab, prior to
treatment and 6–12 weeks after initiation of therapy. Multi-
parametric flow cytometry was used to identify CTCs and
evaluate the expression of PD-L1.
Results. CTCs were detected in 25 of 40 patients (63%).
Patients with detectable PD-L1+ CTCs (14/25, 64%) had
significantly longer progression-free survival (PFS) com-
pared with patients with PD-L1− CTCs (26.6 months vs.
5.5 months; p = .018). The 12-month PFS rates were 76%
versus 22% in the PD-L1+ versus PD-L1− CTCs groups
(p = .012), respectively. A multivariate linear regression
analysis confirmed that PD-L1+ CTC is an independent pre-
dictive biomarker of PFS (hazard ratio, 0.229; 95% confi-
dence interval, 0.052–1.012; p = .026).
Conclusion. Our results reveal the potential of CTCs as a non-
invasive real-time biopsy to evaluate PD-L1 expression in
patients with melanoma. PD-L1 expression on CTCs may be
predictive of response to pembrolizumab and longer PFS.
The Oncologist 2019;24:1–8
Implications for Practice: The present data suggest that PD-L1 expression on circulating tumor cells may predict response to
pembrolizumab in advanced melanoma. This needs further validation in a larger trial and, if proven, might be a useful liquid
biopsy tool that could be used to stratify patients into groups more likely to respond to immunotherapy, hence leading to health
cost savings.
INTRODUCTION
Advanced melanoma is an aggressive cancer with poor
prognosis. However, the survival outcomes have improved
recently for a proportion of these patients with the intro-
duction of new immune modulating agents [1]. Biomarkers
identifying these patients are lacking. Furthermore, these
agents are expensive and can lead to substantial immune-
related toxicity that can place a huge economic burden on
the health system.
A number of tumor and immune biomarkers are cur-
rently under development in an effort to better predict
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treatment responders to immunotherapy [2]. Despite its
caveats, PD-L1 expression is the most studied and developed
biomarker so far in immuno-oncology. Tissue PD-L1 expres-
sion assessed via immunohistochemistry (IHC) is currently
being used in the management of advanced lung cancer [3].
A number of studies have demonstrated higher response in
patients with high PD-L1 expression in their tumors [3–5].
Tissue biopsy is the current gold standard for cancer
diagnosis and for determining prognosis in certain cases [6].
However, this can be invasive and uncomfortable to the
patients and lead to complications. A single biopsy only pro-
vides a limited snapshot of cancer at that particular time.
As our understanding of tumor biology has improved over
the last decade, we now know that cancer evolves with
time and can undergo escape mutations and epigenetic
alterations with dynamic molecular changes [7, 8]. This can
lead to resistance to therapy and disease progression, fac-
tors that cannot be determined from a single biopsy.
Liquid biopsies can provide useful genomic information
that could be complementary to tissue biopsy. They are rel-
atively noninvasive and can track tumor evolution longitudi-
nally through serial sampling at various time points [9].
Tumor cells spread through blood vessels and can be cap-
tured using various techniques. Molecular analysis of these
circulating tumor cells (CTCs) can provide useful molecular
information regarding the parent tumors [10–12]. Such
information can enhance our understanding of response
and resistance mechanisms to immunotherapy.
Previously we reported on the heterogeneity of mela-
noma CTCs and the prognostic value of CTC subpopula-
tions in patients undergoing mitogen-activated protein
kinase inhibiting therapies [13]. Here we use the same
multiparametric flow cytometry panel to detect CTCs in
patients commencing pembrolizumab therapy and evalu-
ate the expression of PD-L1 on CTCs in relation with
response to treatment and survival. The primary objective
of the study was to assess the predictive significance
of pretreatment CTC PD-L1 expression for response and pro-
gression-free survival (PFS). Secondary objectives included
predictive significance of pharmacodynamic changes in total
CTC count and in the percentage of PD-L1–expressing CTCs
(CTC PD-L1+) during treatment and its impact on response to
pembrolizumab.
MATERIALS AND METHODS
Patients, Treatment, and Blood Collection
Patients were recruited from three clinical sites in Perth,
Western Australia. Patients were diagnosed and staged
according to the guidelines of the American Joint Commit-
tee on Cancer, 8th edition. Participants signed informed
consent with the clinician in accordance with protocols
safeguarding patient rights. All procedures were accepted
by the Human Research Ethics Committees at Edith Cowan
University (no. 11543) and Sir Charles Gairdner Hospital
(no. 2013-246).
Peripheral blood samples were obtained from each
patient prior to commencement of treatment (baseline)
with pembrolizumab and then every 6–12 weeks. Blood
was drawn into K2-EDTA tubes (BD Biosciences, San Jose,
CA, USA) after discarding the first 2–3 mL to avoid epithelial
contamination and refrigerated at 4C until use. Samples
were processed within 24 hours from collection.
Flow Cytometric Staining
Peripheral blood mononuclear cells (PBMCs) were isolated
from 2 × 8 mL of blood using Ficoll-Paque (GE Healthcare,
Chicago, IL), washed in FACS buffer (0.1% bovine serum albu-
min, 100 mM EDTA, 10 mM HEPES, and phosphate-buffered
saline), and stained immediately for flow cytometry analysis
as described previously [13]. Prior to antibody staining, cells
were incubated for 10 minutes with Fc-Blocking Reagent
(Miltenyi Biotec, Bergisch Gladbach, Germany). The total
number of PBMCs isolated from 8 mL of blood was stained
with antibodies to MCAM-PECy7, MCSP-APC, ABCB5-PE.TxR,
CD271-PerCPCy5.5, RANK-PE, PD-L1.AF488, CD45-APC.AF750,
and CD34-AF700 (supplemental online Table 1). PBMCs from
the second 8 mL of blood were stained using isotype controls
for PECy7, APC, PE.TxR, PerCPCy5.5, PE, and AF488 and sta-
ined with CD45-APC.AF750 and CD34-AF700. Samples were
incubated for 30 minutes at 4C in the dark. After two
washes with FACS buffer to remove unbound antibodies,
cells were incubated with Live/Dead Fixable Aqua Dead Cell
Stain Kit (Thermo Fisher Scientific, Waltham, MA), fixed, and
stained with Hoechst 33342 (Thermo Fisher Scientific). The
cell suspension was then acquired to exhaustion in a Gallios
Flow Cytometer (Beckman Coulter, Brea, CA). Data were ana-
lyzed using the Kaluza analysis software (version 1.2,
Beckman Coulter; gating strategy exemplified in supplemen-
tal online Fig. 1). The sample stained with isotype controls
was used to define the gates. A cell was identified as a CTC if
it was Aqua Vital negative (live) and Hoechst positive (nucle-
ated) and demonstrated positive staining for MCAM, MCSP,
ABCB5, CD271, or RANK and negative stains for CD45 and
CD34. PD-L1 expression was evaluated on the cells identified
as CTCs.
Treatment Response and Disease Progression
Assessment
Tumor responses were assessed radiologically by computed
tomography (CT) and/or positron electron tomography
(PET) scans at two to three monthly intervals. Response
(decrease in standardized uptake value/size/number of
lesions on PET or decrease in size/number of lesions on CT
scan as per RECIST 1.1) to treatment was defined on the
basis of individual PET or CT scan reports by a radiologist
blinded to clinical data) and the treating oncologist’s inter-
pretation of imaging findings correlated with clinical benefit
from therapy. PFS was defined as the time interval between
the start of therapy and the date of first progression. Over-
all survival (OS) was defined as the time interval between
the start of therapy and death.
Immunohistochemistry for Assessment of PD-L1
Expression in Tumor Tissue
Immunohistochemistry for PD-L1 expression was performed
as described previously [14], using the PD-L1 IHC 22C3 phar-
mDx (Dako, Carpinteria, CA) and approved by the U.S. Food
and Drug Administration for use in non–small-cell lung
© 2019 The Authors.
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cancer. Verification of successful reaction on each slide was
assessed with tonsil and placenta as external tissue con-
trols. PD-L1 expression was assessed based on the Tumor
Proportion Score (TPS) by an experienced pathologist (B.A.).
Only viable tumor cells were assessed. Positivity is defined
as any perceptible linear cell membrane staining (partial or
complete), the score reflects percentage of positive tumor
cells, and any associated immune cells are excluded from
scoring.
Statistical Analysis
Patients were dichotomized into those with at least one
PD-L1–positive CTC (CTC PD-L1+) and those with PD-L1–
negative CTCs (CTC PD-L1−). Receiver operating characteris-
tic (ROC) curve was used to determine the best cutoff value
to discriminate between responder and nonresponders.
Univariate logistic regression model was then used to estab-
lish the odds ratio and 95% confidence interval (CI) at the
optimal cutoff. Fisher’s exact tests were used to assess the
association between PD-L1+ CTCs or PD-L1 expression in
tumors and response to treatment, as well as the associa-
tion between changes in total and PD-L1+ CTCs upon treat-
ment initiation and response to treatment. Survival curves
were plotted using the Kaplan-Meier method and hazard
ratios computed through a Mantel-Cox analysis. Univariate
and multivariate Cox proportional hazards regression
models were used to evaluate the association of PD-L1+
CTCs and progression-free and overall survival. Analyses
were performed using GraphPad Prism 8.2.0 (GraphPad
Software, San Diego, CA) and IBM SPSS Statistics version
25 (IBM, Armonk, NY).
RESULTS
Patient Characteristics and PD-L1 Detection on CTCs
A total of 58 patients treated with pembrolizumab either as
first- or second-line therapy were recruited between
September 2014 and September 2017. Here we present the
data of 40 patients for whom blood samples were collected
prior to treatment initiation (baseline) and flow cytometric
analysis passed quality control criteria. Baseline patient
characteristics are summarized in Table 1. Median follow-
up duration was 25.5 months (range, 9.4–42.4 months);
23 (57%) patients were alive at time of analysis, and
15 (37%) patients had ongoing treatment response at time
of analysis. For the total cohort, the response rate was 53%,
the 1-year PFS was 52%, and 1-year OS was 66%.
CTCs were detected in 25 of the 40 patients (63%), rang-
ing from 7 to 291 cells in 8 mL of blood (Fig. 1A). CTCs were
highly heterogeneous, commonly expressing the tumor-
initiating markers ABCB5 and/or RANK, whereas MCAM-
and MCSP-expressing CTCs were seen in a minority of cases.
PD-L1 was identified in 16 of the 25 individuals (64%) with
detectable CTCs at baseline. The percentage of CTCs
expressing PD-L1 varied widely, ranging between 1% and
89% (Fig. 1B). The majority of PD-L1+ CTCs expressed ABCB5
and/or RANK as the major markers of the CTCs. However,
PD-L1 expression was also found in MCSP+ CTCs in
patient MM91.
Prognostic Value of PD-L1–Expressing CTCs
Within the 25 patients with detectable CTCs, those with PD-
L1+ CTCs had significantly longer PFS compared with
patients with PD-L1− CTCs (p = .009; Fig. 2A), with a hazard
ratio of 0.162 (95% CI 0.042–0.631). The median PFS for the
PD-L1− CTCs group was 5.5 (5.2–5.8) months, whereas
median PFS was not reached for the group with PD-L1+
CTCs. The 12-month PFS rates were 81% versus 22% in the
PD-L1+ versus PD-L1− CTCs groups, respectively (p = .034).
Interim overall survival analysis did not reveal statistically
significant differences between the groups, although sur-
vival rates were lower in patients with PD-L1− CTCs
(Fig. 2B), with median OS not reached in the group with PD-
L1+ CTCs.
Multivariate Cox regression analysis controlling for age,
sex, line of therapy, disease stage, BRAF status, Eastern
Cooperative Oncology Group (ECOG) status, neutrophil-to-
lymphocyte ratio, and presence of liver metastases confirmed
that CTC PD-L1 positivity is an independent predictive bio-
marker of PFS (hazard ratio, 0.11; 95% CI, 0.01–0.81; p = .03;
Table 2).
Table 1. Patient characteristics
Characteristic n (%)
Total 40
Age (mean, 71 years)
<70 17 (43)
>70 23 (58)
Gender
M 28 (70)
F 12 (30)
M stage
M1b 3 (8)
M1c 29 (73)
M1d 8 (20)
Line of treatment
First 25 (63)
Second 14 (35)
Third 1 (3)
BRAF status
WT 26 (65)
V600E 9 (23)
V600K 1 (3)
V600R 2 (5)
Others 2 (5)
NLR
≥5 11 (28)
<5 29 (72)
Liver metastases
Yes 9 (23)
No 31 (77)
Abbreviations: F, female; M, male; NLR, neutrophil-to-lymphocyte
ratio; WT, wild type.
© 2019 The Authors.
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PD-L1+ CTCs and Response to Pembrolizumab
There were 21 responders and 19 nonresponders to pembro-
lizumab monotherapy. The total number of CTCs was similar
and did not significantly differ between responders and nonre-
sponders, and there were no differences in PFS or OS between
patients with detectable and nondetectable CTCs. However,
the number of PD-L1+ CTCs was significantly higher in
responders (p = .005; Fig. 3). We applied a univariate logistic
regression model and ROC curve to assess whether CTC PD-L1
positivity distinguished responders from nonresponders to
pembrolizumab monotherapy (Fig. 3C). Using a cutoff of at
least one PD-L1+ CTC, we observed a 61.9% sensitivity with an
84.2% specificity. Among patients with detectable CTCs,
patients with PD-L1+ CTCs were eight times more likely to be
Figure 1. CTCs in detected in patients with advanced melanoma prior to treatment with pembrolizumab. (A): Number of CTCs in
8 mL of blood corresponding to each of the CTC subpopulations identified. Each bar represents a single patient with melanoma.
Absent bars represent patients in whom CTCs were not detected. (B): Proportion of total CTCs (full bars) that express PD-L1 (red
bars) at baseline in patients treated with pembrolizumab monotherapy. Patients were grouped based on therapeutic objective
response. Tumor Proportion Scores indicating PD-L1 expression in the tumor tissue are indicated for each patient. (-) indicates not
available tissues.
Abbreviation: CTC, circulating tumor cell.
BA
Figure 2. Kaplan-Meier plots of progression-free survival and overall survival according to PD-L1 expression on CTCs prior to treat-
ment initiation. (A): Progression-free survival. (B): Overall survival.
Abbreviations: CI, confidence interval; CTC, circulating tumor cell; HR, hazard ratio.
© 2019 The Authors.
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responders compared with patients with undetectable PD-L1+
CTCs (OR, 8.67; 95% CI, 1.19–342.96; p = .017; Table 3; supple-
mental online Fig. 2A).
Comparison of CTCs detected at baseline and after
6–12 weeks after treatment initiation (follow-up) showed
that the total number of CTCs, as well as the proportion of
CTCs expressing PD-L1, decreased upon treatment in most
responders and increased or remained the same in most
nonresponders (Fig. 4).
PD-L1 Expression in Matching Tumor Samples
Available archival melanoma specimens were tested for
PD-L1 analysis in 25 of the 40 patients. Fourteen cases had
PD-L1 status data available for both the tumor and CTCs
samples (Fig. 1B). Six patients were PD-L1+ in both tumor
and CTCs, and all of them responded to therapy. Three
patients were PD-L1+ in tumor (≤10% TPS) but not on CTCs,
and two of them responded to treatment. Two patients
were PD-L1+ on CTCs but not in tissue, with one responding
and the other not responding to treatment. Finally, three
patients were PD-L1− in both tissue and CTCs, and all failed
to respond. Representative images of PD-L1 staining are
shown in supplemental online Figure 3.
PD-L1 positivity in tumor tissue (≥1% TPS) was significantly
associated with response to treatment (p = .027; supplemental
online Fig. 2B). Furthermore, there were more responders in
the PD-L1+ cohort irrespective of PD-L1 assessment through
Table 2. Progression-free survival univariate and multivariate Cox regression analysis
Variable Group
Univariate Multivariate
p value Hazard ratio (95.0% CI) p value Hazard ratio (95.0% CI)
PD-L1+ CTCs Positive vs negative .020 0.20 (0.05–0.77) .030 0.11 (0.01–0.81)
ECOG ≥1 vs 0 .408 1.26 (0.73–2.18) .050 11.00 (1.00–120.83)
Age Continue .378 0.98 (0.94–1.03) .328 0.97 (0.90–1.03)
Sex M vs. F .652 0.87 (0.48–1.59) .226 0.18 (0.01–2.92)
Stage M1c/d vs. M1a/b .279 1.54 (0.71–3.35) .111 9.65 (0.59–157.13)
BRAF Mutant vs. WT .219 1.41 (0.81–2.45) .026 164.05 (1.86 to 1.45E+04)
Line of therapy 1st vs. 2nd/3rd .217 2.03 (0.66–6.26) .945 1.8E-04 (6.5E-112 to 4.7E+103)
NLR >5 vs. <5 .003 0.12 (0.03–0.49) .909 5.6E-07 (2.1E-114 to 1.5E+101)
Liver metastases Yes vs. no .713 0.75 (0.17–3.42) .256 0.20 (0.01–3.19)
Abbreviations: CI, confidence interval; CTC, circulating tumor cell; ECOG, Eastern Cooperative Oncology Group; F, female; M, male;
NRL, neutrophil-to-lymphocyte ratio; WT, wild type.
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Table 3. Comparison of response to pembrolizumab relative
to PD-L1 detection in CTCs
Response
PD-L1+ CTCs
(n = 16), n (%)
PD-L1− CTCs
(n = 9), n (%)
CTC−
(n = 15),
n (%)
Best overall
response
Complete
response
6 (38) 1 (11) 4 (27)
Partial
response
7 (44) 2 (22) 1 (7)
Stable
disease
0 (0) 2 (22) 0 (0)
Progressive
disease
3 (19) 4 (44) 10 (67)
Objective
response rate
13 (81) 3 (33) 5 (33)
Abbreviation: CTC, circulating tumor cell.
© 2019 The Authors.
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tissue or CTCs (p = .0073; supplemental online Fig. 2C),
suggesting that themethods could be complementary.
DISCUSSION
Here we evaluated the expression of PD-L1 on melanoma
CTCs. Our results indicated that PD-L1 positivity in CTCs is
an independent predictor of response and prolonged PFS in
patients with melanoma treated with pembrolizumab. CTC-
based PD-L1 status was superior to other baseline clinical
parameters associated with response and prognosis, includ-
ing lactate dehydrogenase, disease stage, and ECOG perfor-
mance status.
A number of biomarkers, including tumor PD-L1 expres-
sion, tumor mutational burden, tumor-infiltrating lympho-
cytes, and immune gene signature, have been evaluated in
various studies with encouraging results [2]. In particular,
PD-L1 expression in tumors has been shown to be associ-
ated with response to anti–PD-1 therapies in melanoma
and other cancers [3–5, 15]. Thus, efforts have been made
to investigate the performance of CTCs as a surrogate to
assess PD-L1 expression in the bloodstream of several
tumor types [16, 17]. Our study is the first to evaluate the
predictive significance of blood-based CTC PD-L1 expression
for response to anti–PD-1 therapy in advanced melanoma.
The results further validated our previous observations
regarding the heterogeneity of melanoma CTCs using this
flow cytometry–based method [13]. Similarly, the heteroge-
neity of melanoma CTCs has also been demonstrated using
other isolation and detection methodologies [18–20]. Previ-
ous studies have shown that that number of CTCs in
patients with melanoma at baseline is prognostic of survival
[21]. However, in our study we did not find that the pre-
treatment total CTC number was associated with survival or
response to treatment. This may be affected by the effec-
tiveness of pembrolizumab to divert the natural disease
progression regardless of tumor burden. Similarly, in a
recent study by Hong et al. [22], using a combination of a
microfluidic device and 19 transcripts for detection of mela-
noma CTCs, no correlation was found between baseline CTC
scores and survival or response to treatment. In addition,
the authors noted that using serial monitoring of patients
with melanoma treated with immune checkpoint inhibitors,
rapid decline in CTC score preceded response by standard
clinical assessment and was highly predictive of long-term
clinical outcome. This is highly concordant with our observa-
tion that a decline in total CTCs upon treatment initiation
was strongly associated with response to treatment. Thus,
longitudinal blood collection for CTC PD-L1 analysis may
assist with differentiation between responders and nonre-
sponders or pseudoprogressors early in therapy.
Our results indicate better response rates in patients with
PD-L1+ CTCs at baseline and in those in whom the proportion
of PD-L1+ CTCs decreased a few weeks into treatment. This
study also demonstrated better median and 12-month PFS
for PD-L1+ CTC compared with PD-L1− CTC. Currently, there
is no biomarker in routine use for guiding treatment of
patients with melanoma with immunotherapy and differenti-
ating between responders and nonresponders. Validation of
these results in larger prospective trials in the future might
assist clinicians to stratify their patients into potential
responders and nonresponders and change treatment earlier
to alternative therapies or combination therapies for those
less likely to respond.
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We compared PD-L1 detection on CTCs with that of
matching tumor tissues. PD-L1 expression was assessed as a
percentage of tumor cells in tissue for better comparison
with CTCs, rather than using the melanoma scoring system
(MEL) as reported by Daud et al. [23]. Patients with PD-L1
positivity on CTCs or tumor tissue have a high probability of
response, suggesting that the methods could be comple-
mentary. Of note, concordant results in tissue and CTCs
(n = 9) predicted response to treatment with a 100%
accuracy.
There are a number of limitations to this study. Sample
size is small, and these results need to be validated in a
larger independent, prospective cohort. CTCs were not
detectable in about a third of patients, which could be
related to disease biology or technical limitations. For com-
parison, circulating tumor DNA is detectable in around
43%–76% of patients with advanced melanoma [24–26],
suggesting that circulating markers are below detection in
some patients with melanoma despite disseminated dis-
ease. There was no standardization of imaging modalities
used to assess response to treatment. However, our data
are reflective of the real-world setting and routine clinical
practice outside the context of a clinical trial where RECIST
1.1 is not formally used and the choice of imaging modality
varies among clinicians.
CONCLUSION
Our research suggests that the presence of PD-L1–expressing
CTCs is associated with treatment response to pembrolizumab.
Patients with one or more PD-L1+ CTCs had a higher response
rate to pembrolizumab as well as longer PFS. This study pro-
vides a proof of concept that detecting PD-L1 status through a
liquid biopsy can provide clinically relevant information.
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